Article
Medicine, General & Internal
Carrie M. Mintz, Kevin Y. Xu, Ned J. Presnall, Sarah M. Hartz, Frances R. Levin, Jeffrey F. Scherrer, Laura J. Bierut, Richard A. Grucza
Summary: The use of prescription stimulants is associated with a modest increase in the risk of drug-related poisoning among individuals receiving buprenorphine treatment for opioid use disorder (OUD). However, stimulant use is also associated with improved retention to buprenorphine treatment, providing protection against overdose.
Article
Biochemistry & Molecular Biology
Cruz Reyes-Vasquez, Zachary Jones, Bin Tang, Nachum Dafny
Summary: Methylphenidate, known as Ritalin, is a psychostimulant drug used to treat various age groups. This study investigates the effects of chronic Methylphenidate administration on neuronal activity and behavioral response in different brain regions. The results show that chronic Methylphenidate can elicit behavioral sensitization or tolerance, and different brain areas exhibit varying neuronal responses. The findings suggest that dopamine, norepinephrine, and serotonin in specific brain regions have distinct effects.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Substance Abuse
Heidar Sharafi, Hamzah Bakouni, Christina McAnulty, Sarah Drouin, Stephanie Coronado-Montoya, Arash Bahremand, Paxton Bach, Nadine Ezard, Bernard Le Foll, Christian G. Schutz, Krista J. Siefried, Vitor S. Tardelli, Daniela Ziegler, Didier Jutras-Aswad
Summary: This systematic review with meta-analysis aimed to evaluate the efficacy and safety of prescription psychostimulants (PPs) for amphetamine-type stimulant use disorder (ATSUD). The analysis found that treatment with PPs may decrease ATS use and craving, but the effect size is limited and may increase with a higher dosage of medications.
Article
Psychiatry
Isabell Brikell, Theresa Wimberley, Clara Albinana, Emil Michael Pedersen, Bjarni Johann Vilhjalmsson, Esben Agerbo, Ditte Demontis, Anders D. Borglum, Andrew J. Schork, Sonja LaBianca, Thomas Werge, Ole Mors, David M. Hougaard, Anita Thapar, Preben Bo Mortensen, Soren Dalsgaard
Summary: Individuals with ADHD who have higher polygenic liability for mood and/or psychotic disorders, delayed ADHD diagnosis, and psychiatric comorbidities are at a higher risk for discontinuation of stimulant treatment and switch to nonstimulants. Despite the limited sample size, potential GWAS hits for switch were identified, highlighting the possibility of utilizing genomics linked to prescription databases for advancing ADHD pharmacogenomics.
AMERICAN JOURNAL OF PSYCHIATRY
(2021)
Article
Neurosciences
Felipe Schmitz, Josiane S. Silveira, Gianina T. Venturin, Samuel Greggio, Guilherme Schu, Eduardo R. Zimmer, Jaderson Costa Da Costa, Angela T. S. Wyse
Summary: The study found that MPH treatment can affect glucose metabolism in different regions of the rat brain, leading to a rewiring of the brain's metabolic network and behavioral changes.
NEUROTOXICITY RESEARCH
(2021)
Review
Pharmacology & Pharmacy
Monika Kaurav, Sakina Ruhi, Husni Ahmed Al-Goshae, Ashok Kumar Jeppu, Dhani Ramachandran, Ram Kumar Sahu, Ashish Kumar Sarkar, Jiyauddin Khan, Abu Md Ashif Ikbal
Summary: A brain tumor is an uncontrolled cell proliferation that grows and divides abnormally. Approximately 25,690 primary malignant brain tumors are discovered each year, with 70% originating in glial cells. Nanocarriers have shown significant therapeutic efficacy in various brain diseases.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Public, Environmental & Occupational Health
Philipp Dominik, Martin P. Wassmer, Michael Soyka, Andreas G. Franke
Summary: Pharmacological neuroenhancement refers to the use of psychoactive substances to enhance mental performance without medical need, with users often considering it as a coping strategy. In Germany, the use of freely available and prescription drugs, as well as narcotics without medical indication, has not been subject to clear legal sanctions, but this could pose risks to the lives and health of others.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Psychology, Developmental
Sean Esteban McCabe, Olivia Figueroa, Vita V. McCabe, Ty S. Schepis, John E. Schulenberg, Philip T. Veliz, Kennedy S. Werner, Timothy E. Wilens
Summary: This study aimed to examine the relationship between age of onset and duration of stimulant therapy for ADHD and cocaine, methamphetamine, and prescription stimulant misuse in adolescence. The results showed that early initiation and longer duration of stimulant therapy were not associated with increased odds of cocaine or methamphetamine use. However, late initiation and shorter duration of stimulant therapy were significantly associated with higher odds of past-year cocaine or prescription stimulant misuse. There were no differences in misuse rates between individuals who received non-stimulant therapy for ADHD and those who initiated early and long-duration stimulant therapy.
JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY
(2023)
Review
Biochemistry & Molecular Biology
Milky Kohno, Laura E. Dennis, Holly McCready, William F. Hoffman
Summary: This review compares the epidemiology of cocaine and methamphetamine use disorder, discusses the effects of drugs on the dopamine system, and summarizes treatment results from pharmacological clinical trials.
MOLECULAR PSYCHIATRY
(2022)
Article
Biochemistry & Molecular Biology
Luis C. Farhat, Jose M. Flores, Emily Behling, Victor J. Avila-Quintero, Adam Lombroso, Samuele Cortese, Guilherme Polanczyk, Michael H. Bloch
Summary: We conducted a large-scale systematic review and meta-analysis to examine the effects of stimulant dose and dosing strategies on clinical outcomes in children/adolescents with ADHD. Our findings suggest that flexible titration of stimulant medications can improve efficacy and acceptability.
MOLECULAR PSYCHIATRY
(2022)
Article
Clinical Neurology
Christina Weyer-Jamora, Melissa S. Brie, Tracy L. Luks, Ellen M. Smith, Shawn L. Hervey-Jumper, Jennie W. Taylor
Summary: Intrinsic brain tumors often occur within functional neural networks, and postoperative cognitive rehabilitation is the standard treatment for addressing postoperative cognitive impairments.
Review
Medicine, General & Internal
Chris Eaton, Kenneith Yong, Victoria Walter, Gashirai K. Mbizvo, Sinead Rhodes, Richard Fm Chin
Summary: This study assessed the efficacy of stimulant and non-stimulant drugs used to treat individuals with both ADHD and epilepsy. The results showed that the stimulant drug OROS-MPH did not significantly worsen epilepsy, but higher doses were associated with an increased risk of seizures. The non-stimulant drug omega-3, when used in combination with other medications, reduced seizure frequency. However, the certainty of evidence for these outcomes was low, and further research is needed.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2022)
Review
Biochemistry & Molecular Biology
Kiarash Eskandari, Mojdeh Fattahi, Hassan Yazdanian, Abbas Haghparast
Summary: Deep brain stimulation (DBS) is a promising treatment for psychostimulant addiction, but further research is needed to fully understand its therapeutic effects and mechanisms. This review summarizes the positive and adverse effects of DBS and highlights the need for controlled studies and research on animals and humans to optimize stimulation parameters and develop less invasive methods.
NEUROCHEMICAL RESEARCH
(2023)
Review
Pharmacology & Pharmacy
Kathrine Louise Jensen, Soren Brogger Jensen, Kenneth Lindegaard Madsen
Summary: Psychostimulant use disorder is a major global health issue with no effective pharmacological treatments available. This review provides an overview of pharmacological treatments targeting different aspects of psychostimulant addiction, including the dopamine system, the glutamate system, and the severe side effects of quitting long-term use. Promising results have been found with drugs modulating the dopamine system, cognitive enhancers, and drugs targeting the glutamate system, but further research is needed for sufficient evidence of efficacy and tolerability.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Clinical Neurology
Marina Silva de Lucca, Maria Eduarda Oliveira Pimentel, Cleuberton Kenedy Oliveira Raimundo, Bruno David Henriques, Tiago Ricardo Moreira, Silvia Almeida Cardoso, Debora Marques de Miranda
Summary: This review investigates the relationship between brain-derived neurotrophic factor (BDNF) levels in ADHD children before and after treatment with stimulant medication. The findings suggest that there is no significant difference in peripheral BDNF levels before and after methylphenidate treatment in ADHD children, and BDNF levels also do not differ from controls.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2023)
Article
Rehabilitation
K. Gehring, N. K. Aaronson, M. J. B. Taphoorn, M. M. Sitskoorn
CLINICAL REHABILITATION
(2011)
Review
Oncology
Karin Gehring, Jan Anne Roukema, Margriet M. Sitskoorn
EXPERT REVIEW OF ANTICANCER THERAPY
(2012)
Article
Clinical Neurology
Karin Gehring, Neil K. Aaronson, Chad M. Gundy, Martin J. B. Taphoorn, Margriet M. Sitskoorn
JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY
(2011)
Correction
Clinical Neurology
Karin Gehring, Neil K. Aaronson, Chad M. Gundy, Martin J. B. Taphoorn, Margriet M. Sitskoorn
JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY
(2011)
Article
Clinical Neurology
Hanneke E. Hulst, Karin Gehring, Bernard M. J. Uitdehaag, Leo H. Visser, Chris H. Polman, Frederik Barkhof, Margriet M. Sitskoorn, Jeroen J. G. Geurts
MULTIPLE SCLEROSIS JOURNAL
(2014)
Article
Oncology
Eline Verhaak, Karin Gehring, Patrick E. J. Hanssens, Margriet M. Sitskoorn
JOURNAL OF NEURO-ONCOLOGY
(2019)
Article
Oncology
Eline Verhaak, Wietske C. M. Schimmel, Margriet M. Sitskoorn, Marjan Bakker, Patrick E. J. Hanssens, Karin Gehring
JOURNAL OF NEURO-ONCOLOGY
(2019)
Article
Oncology
Wietske C. M. Schimmel, Karin Gehring, Patrick E. J. Hanssens, Margriet M. Sitskoorn
JOURNAL OF NEURO-ONCOLOGY
(2019)
Review
Oncology
Eline Verhaak, Karin Gehring, Patrick E. J. Hanssens, Neil K. Aaronson, Margriet M. Sitskoorn
SUPPORTIVE CARE IN CANCER
(2020)
Article
Oncology
Eline Verhaak, Wietske C. M. Schimmel, Karin Gehring, Wilco H. M. Emons, Patrick E. J. Hanssens, Margriet M. Sitskoorn
Summary: The study found that over 9 months, patients' physical well-being worsened while emotional well-being improved at group level. However, at individual level, most patients experienced declines in physical well-being and improvements in emotional well-being. Overall, aspects of HRQoL remained stable except for emotional well-being and physical well-being varied considerably at the individual patient level.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Oncology
Sophie D. van der Linden, Geert-Jan M. Rutten, Linda Dirven, Martin J. B. Taphoorn, Djaina D. Satoer, Clemens M. F. Dirven, Margriet M. Sitskoorn, Karin Gehring
Summary: This study aimed to evaluate the effects of a tablet-based cognitive rehabilitation program for brain tumor patients, showing no significant effects but good adherence and satisfaction with the eHealth program. Recruitment difficulties and limited statistical power were identified as challenges of the study.
JOURNAL OF NEURO-ONCOLOGY
(2021)
Meeting Abstract
Oncology
Karin Gehring, Petra Hoogendoorn, Margriet Sitskoorn
Meeting Abstract
Clinical Neurology
H. Schreiber, C. Lang, K. Kiltz, M. Lang, P. Flachenecker, H. Meissner, M. Freidel, H. Herbst, E. Scholz, W. Hofmann, E. Schlegel, W. Elias, K. Gehring, U. Eckhardt, A. Bergmann, G. Reifschneider, S. Ries, C. Ring, S. Schlegel
MULTIPLE SCLEROSIS JOURNAL
(2012)
Meeting Abstract
Clinical Neurology
H. E. Hulst, K. Gehring, B. M. J. Uitdehaag, L. H. Visser, C. H. Polman, F. Barkhof, M. M. Sitskoorn, J. J. G. Geurts
MULTIPLE SCLEROSIS JOURNAL
(2012)